DIRS.INFO The most relevant business & tech news

☆ Insider Today: Work out smarter
▼ + stars: | 2024-12-14 | by ( Joi-Marie Mckenzie | ) www.businessinsider.com time to read: +6 min

This post originally appeared in the Insider Today newsletter. She's a Business Insider fellow who asked ChatGPT what to get her family for Christmas. AdvertisementThe AI-powered tool "gave me 19 suggestions," Brew wrote, "along with additional ideas under categories suggesting quirky and personalized gifts." : Time is running out for gift shopping, but luckily, we have a guide to the best last-minute gift ideas for when you're in a pinch. More of this week's top reads:AdvertisementThe Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York City.

Persons: Natalie Ammari, Caroline Brew's, ChatGPT, Brew, we've, BI's, cancer's, Herman Miller, Jason McDonald, Chelsea Jia Feng, Lia Bartha, Moritz, Alessandro Bellani, Barts, Ralph Fiennes, Stanley Tucci, Maria, Angelina Jolie, Maria Callas, Rebecca Zisser, they've, Dan DeFrancesco, Grace Lett, Lisa Ryan, Amanda Yen Organizations: Business, Alpha, SDI, Lancet Oncology, BI, Netflix Locations: St, Los Angeles, New York City, New York

☆ Op-ed: The financial toxicity of cancer is growing. Here's what can be done to reduce it
▼ + stars: | 2024-10-18 | by ( Karen Knudsen | American Cancer Society Ceo | ) www.cnbc.com time to read: +5 min

Cancer drains individuals of their physical, emotional, and financial health. In a study from the American Cancer Society Cancer Action Network, nearly half of cancer patients and survivors reported being extraordinarily burdened by medical debt. Financial hardship caused by cancer can also contribute to "financial toxicity," wherein the cost of treatment forces individuals to make tradeoffs that impact their chances of survival. Not only does financial toxicity of cancer care affect the individual, it can also negatively impact their employer. Some may not be aware they're eligible for screening, and stigma and fear associated with cancer screening hinders some people from seeking care.

Persons: — Organizations: American Cancer Society Cancer Action Network, ACS Locations: U.S, United States

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal
▼ + stars: | 2023-03-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Pfizer CEO Albert Bourla on Monday said the pharmaceutical giant will be able to deliver Seagen's cancer therapy to the world "at a scale that has not been seen before" with its $43 billion acquisition. Seagen will bulk up Pfizer's cancer treatment portfolio, bringing four approved cancer therapies with combined sales of nearly $2 billion in 2022. "These medicines are on a strong growth trajectory, with significant lifecycle programs anticipated to drive continued impact uptake and growth," Bourla said on a conference call earlier Monday morning. Seagen expects to generate about $2.2 billion in revenue this year, representing 12% year-over-year growth, according to a Pfizer press release. Pfizer added that Seagen could contribute more than $10 billion in risk-adjusted sales by 2030, "with potential for significant growth" beyond that year.

☆ Moderna's combination skin cancer therapy receives FDA's breakthrough tag
▼ + stars: | 2023-02-22 | by ( ) www.reuters.com time to read: +1 min

Feb 22 (Reuters) - Moderna Inc (MRNA.O) said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's (MRK.N) drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients. The breakthrough tag is granted by the U.S. Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone. The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition. The companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023. Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli and Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "cancer's"

5 mentions found